1,248 results on '"Gelmon, Karen"'
Search Results
202. The Ongoing Debate About Nodes
203. Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer
204. Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection
205. Adjuvant targeted therapy in early breast cancer
206. Selection of adjuvant chemotherapy for treatment of node-positive breast cancer
207. Tucatinib vs placebo, both combined with capecitabine and trastuzumab, for patients with pretreated HER2-positive metastatic breast cancer with and without brain metastases (HER2CLIMB)
208. PUB0201081895
209. Triple negative breast cancer – Understanding the clinical implications of heterogeneity
210. Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancer
211. Osteoblastic metastases from breast carcinoma with false-negative bone scan
212. Predictors of Supervised Exercise Adherence during Breast Cancer Chemotherapy
213. Predictors of Adherence to Supervised Exercise Training During Breast Cancer Chemotherapy: 2469: Board #52 May 31 8:00 AM - 9:30 AM
214. Moderators of the Effects of Exercise Training in Breast Cancer Patients Receiving Chemotherapy: A Randomized Controlled Trial
215. Risk of Early Recurrence Among Postmenopausal Women With Estrogen Receptor-Positive Early Breast Cancer Treated With Adjuvant Tamoxifen
216. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer
217. Moderators of the Effects of Exercise Training in Breast Cancer Patients Receiving Chemotherapy: 789: June 1 8:45 AM - 9:00 AM
218. Immunohistochemical Detection Using the New Rabbit Monoclonal Antibody SP1 of Estrogen Receptor in Breast Cancer Is Superior to Mouse Monoclonal Antibody 1D5 in Predicting Survival
219. Impact on Survival of Time From Definitive Surgery to Initiation of Adjuvant Chemotherapy for Early-Stage Breast Cancer
220. Pegylated Liposomal Doxorubicin and Trastuzumab in HER-2 Overexpressing Metastatic Breast Cancer: A Multicenter Phase II Trial
221. Effect of continuous statistically standardized measures of estrogen and progesterone receptors on disease-free survival in NCIC CTG MA.12 Trial and BC Cohort
222. Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival
223. Population-Based Validation of the Prognostic Model ADJUVANT! for Early Breast Cancer
224. Locoregional Radiation Therapy in Patients With High-Risk Breast Cancer Receiving Adjuvant Chemotherapy: 20-Year Results of the British Columbia Randomized Trial
225. The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis
226. Use of Trastuzumab Beyond Disease Progression: Observations from a Retrospective Review of Case Histories
227. Impact of the 21-Gene Recurrence Score Assay on the Treatment of Estrogen Receptor-Positive, HER2-Negative, Breast Cancer Patients With 1-3 Positive Nodes: A Prospective Clinical Utility Study.
228. Phase III Study of N,N-Diethyl-2-[4-(Phenylmethyl) Phenoxy]Ethanamine (BMS-217380-01) Combined With Doxorubicin Versus Doxorubicin Alone in Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19
229. 7: Rates of Regional Radiotherapy Receipt Over Time in Low-Risk, Node Positive Breast Cancer
230. Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel
231. Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model
232. The taxoids: paclitaxel and docetaxel
233. Adjuvant systemic therapy and survival after breast cancer
234. Retrospective analysis of continuing use of Herceptin after disease progression in women with HER2-positive metastatic breast cancer (MBC) initially treated with Herceptin plus a taxane
235. Safety Issues of Soy Phytoestrogens in Breast Cancer Patients
236. Effect of Soy Phytoestrogens on Hot Flashes in Postmenopausal Women With Breast Cancer: A Randomized, Controlled Clinical Trial
237. Effect of News Media Coverage of Cancer Risk on Clinical Oncology Practice
238. Phase I Dose-Finding Study of a New Taxane, RPR 109881A, Administered as a One-Hour Intravenous Infusion Days 1 and 8 to Patients With Advanced Solid Tumors
239. One step forward or one step back with tamoxifen?
240. Efficacy and safety of palbociclib in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2.
241. Anticancer Agents Targeting Signaling Molecules and Cancer Cell Environment:Challenges for Drug Development?
242. Abstract PD4-02: Canadian cancer trials group trial IND.231: A phase 1 trial evaluating CX-5461, a novel first-in-class G-quadruplex stabilizer in patients with advanced solid tumors enriched for DNA-repair deficiencies
243. Abstract GS1-01: Tucatinib vs placebo, both combined with capecitabine and trastuzumab, for patients with pretreated HER2-positive metastatic breast cancer with and without brain metastases (HER2CLIMB)
244. Abstract P1-19-16: Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for hormone receptor-positive/human epidermal growth factor receptor 2–negative advanced breast cancer: An updated analysis
245. Abstract P3-08-04: Impact of ER-positivity on time and pattern of relapse in early-stage breast cancer patients
246. Patterns and predictors of exercise behavior during 24 months of follow-up after a supervised exercise program during breast cancer chemotherapy
247. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
248. Patient selection for a developmental therapeutics program using whole genome and Transcriptome analysis
249. Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer
250. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.